Article Details
Retrieved on: 2023-10-11 22:36:04
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Late-breaking data from Roche's Phase III OCARINA II study have revealed that OCREVUS® subcutaneous injection was comparable to IV infusion in ...
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here